苯并硝唑不同剂量治疗成人慢性恰加斯病的疗效与安全性评估:MULTIBENZ研究方案
MULTIBENZ是一项II期随机双盲多中心非劣效性国际临床试验,计划在阿根廷、巴西、哥伦比亚和西班牙招募240例慢性期克氏锥虫感染患者。患者随机接受苯并硝唑150 mg/日×60天、400 mg/日×15天或300 mg/日×60天(对照臂)。主要结局为聚合酶链反应测定的外周血持续寄生虫负荷抑制比例,次要结局涉及药代动力学和药物耐受性,随访12个月。
要点
- 苯并硝唑当前推荐剂量基于非随机研究,最佳剂量方案缺乏临床试验分析。
- MULTIBENZ比较三种剂量方案:150 mg/日×60天、400 mg/日×15天、300 mg/日×60天。
- 主要疗效指标为PCR测定的外周血持续寄生虫负荷抑制比例。
核心结论
- MULTIBENZ试验旨在评估不同苯并硝唑剂量方案治疗慢性期恰加斯病的疗效与安全性,可能帮助明确最适方案。
研究设计与样本
- II期随机双盲多中心非劣效性国际临床试验,计划招募240例慢性期克氏锥虫感染成人患者。
- 招募在阿根廷、巴西、哥伦比亚和西班牙四国进行,随机后随访12个月。
主要发现
- 原文未报告研究结果。
关键数值与推荐
- 干预臂:苯并硝唑150 mg/日×60天、400 mg/日×15天;对照臂:300 mg/日×60天。
- 主要结局:聚合酶链反应测定的外周血持续寄生虫负荷抑制的患者比例。
- 次要结局:药代动力学和药物耐受性。
临床怎么用
- 研究结果可为慢性期恰加斯病苯并硝唑剂量方案选择提供随机对照证据。
局限性
- 原文未报告研究结果,无法评估疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chagas disease (CD) continues to be a neglected infectious disease with one of the largest burdens globally. Despite the modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still the drug of choice. Its current recommended dose is based on nonrandomized studies, and efficacy and safety of the optimal dose of BNZ have been scarcely analyzed in clinical trials. METHODS/DESIGN: MULTIBENZ is a phase II, randomized, noninferiority, double-blind, multicenter international clinical trial. A total of 240 patients with Trypanosoma CD in the chronic phase will be recruited in four different countries (Argentina, Brazil, Colombia, and Spain). Patients will be randomized to receive BNZ 150 mg/day for 60 days, 400 mg/day for 15 days, or 300 mg/day for 60 days (comparator arm). The primary outcome is the efficacy of three different BNZ therapeutic schemes in terms of dose and duration. Efficacy will be assessed according to the proportion of patients with sustained parasitic load suppression in peripheral blood measured by polymerase chain reaction. The secondary outcomes are related to pharmacokinetics and drug tolerability. The follow-up will be 12 months from randomization to end of study participation. Recruitment was started in April 2018. CONCLUSION: This is a clinical trial conducted for the assessment of different dose schemes of BNZ compared with the standard treatment regimen for the treatment of CD in the chronic phase. MULTIBENZ may help to clarify which is the most adequate BNZ regimen in terms of efficacy and safety, predicated on sustained parasitic load suppression in peripheral blood. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03191162. Registered on 19 June 2017.
引用
- Molina-Morant D, Fernández ML, Bosch-Nicolau P, et al. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial. Trials. 2020. PMID: 32293523. doi:10.1186/s13063-020-4226-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。